Group 1 - The core viewpoint of the article is that Citi has released a report indicating that Innovent Biologics (01801) achieved a 38% year-on-year revenue increase to 13 billion RMB, with a net profit of 834 million RMB, marking a turnaround from losses [1] - The management reiterated the guidance for product sales to reach 20 billion RMB by 2027, despite recent price adjustments and increased competition [1] - The sales of Mazdutide continue to show strong momentum, contributing positively to the company's performance [1] Group 2 - Citi has raised its revenue forecasts for the company by 24% and 23% for this year and next year, respectively [1] - Earnings per share estimates have been adjusted upwards by 33% and 5% for the respective years [1] - The target price for the company's stock has been increased from 110 HKD to 115 HKD, maintaining a "Buy" rating [1]
花旗：升信达生物(01801)目标价至115港元 评级“买入”